Metacrine, Inc. (MTCR)

$0.4802

0.00 (0.00%)
Rating:
Recommendation:
-
Symbol MTCR
Price $0.4802
Beta -0.932
Volume Avg. 0.32M
Market Cap 20.442M
Shares () -
52 Week Range 0.303-0.676
1y Target Est -
DCF Unlevered MTCR DCF ->
DCF Levered MTCR LDCF ->
ROE -83.77% Strong Sell
ROA -69.39% Strong Sell
Operating Margin -
Debt / Equity 48.49% Neutral
P/E -
P/B 0.55 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest MTCR news


Ms. Trisha M. Millican
Healthcare
Biotechnology
NASDAQ Global Market

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.